SINGAPORE (Dec 14): Hyphens Pharma, the subsidiary of Hyphens Pharma International, has inked an exclusive licence and supply agreement with DKSH’s subsidiary Favorex to commercialise the Ustekinumab biosimilar in Singapore, Malaysia and the Philippines.
Alvotech is a multinational biopharmaceutical company that focuses on the development and manufacturing of high-quality biosimilars for global markets.
The Ustekinumab biosimilar, a drug that treats...(click on link for full story on theedgesingapore.com)